{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -0.770216, "regularMarketPrice": 1.546, "exchange": "FRA", "shortName": "SELLAS LIFE SCIENCES GRP", "longName": "SELLAS Life Sciences Group, Inc.", "messageBoardId": "finmb_262231850", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": -0.011999965, "regularMarketTime": 1683871252, "regularMarketDayHigh": 1.546, "regularMarketDayRange": "1.546 - 1.546", "regularMarketDayLow": 1.546, "regularMarketVolume": 185, "regularMarketPreviousClose": 1.558, "bid": 1.55, "ask": 1.594, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.546, "averageDailyVolume3Month": 267, "averageDailyVolume10Day": 18, "fiftyTwoWeekLowChange": 0.46449995, "fiftyTwoWeekLowChangePercent": 0.429496, "fiftyTwoWeekRange": "1.0815 - 5.202", "fiftyTwoWeekHighChange": -3.6560001, "fiftyTwoWeekHighChangePercent": -0.7028066, "fiftyTwoWeekLow": 1.0815, "fiftyTwoWeekHigh": 5.202, "earningsTimestamp": 1683835927, "earningsTimestampStart": 1691578740, "earningsTimestampEnd": 1692014400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.12, "epsForward": -1.44, "epsCurrentYear": -1.18, "priceEpsCurrentYear": -1.3101696, "sharesOutstanding": 28347900, "bookValue": 0.231, "fiftyDayAverage": 1.354, "fiftyDayAverageChange": 0.19200003, "fiftyDayAverageChangePercent": 0.14180209, "twoHundredDayAverage": 2.44712, "twoHundredDayAverageChange": -0.90111995, "twoHundredDayAverageChangePercent": -0.36823693, "marketCap": 44640288, "forwardPE": -1.073611, "priceToBook": 6.6926403, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1208152800000, "priceHint": 4, "symbol": "RXK3.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Times Square Tower", "address2": "Suite 2503 7 Times Square", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "646 200 5278", "website": "https://www.sellaslifesciences.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Dr. Angelos M. Stergiou M.D., ScD h.c.", "age": 46, "title": "Founder, Pres, CEO & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 921985, "fmt": "921.99k", "longFmt": "921,985"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Barbara A. Wood Esq.", "age": 59, "title": "Exec. VP, Gen. Counsel & Corp. Sec.", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 632660, "fmt": "632.66k", "longFmt": "632,660"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 8078, "fmt": "8.08k", "longFmt": "8,078"}}, {"maxAge": 1, "name": "Mr. Robert M. Francomano", "age": 55, "title": "Sr. VP & Chief Commercial Officer", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 667354, "fmt": "667.35k", "longFmt": "667,354"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John Thomas Burns CPA", "age": 37, "title": "Sr. VP & CFO", "yearBorn": 1985, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dragan  Cicic M.D., MBA", "age": 59, "title": "Sr. VP of Clinical Devel.", "yearBorn": 1963, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew  Elnatan", "title": "VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}